Eureka’s co-authored paper “Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1,” was published on Monday in Nature Biotechnology. The paper describes a bispecific antibody against intracellular antigen (WT-1) that can cross-prime T cells against new antigens, thus spreading epitopes. The study was performed in collaboration with Memorial Sloan Kettering Cancer Center.
Read the article here: www.nature.com/nbt/journal/vaop/ncurrent/full/nbt.3349.html
Alexa Willson has served as the Chief Financial Officer of Eureka Therapeutics since August 2022. Prior to joining the company, She was a Managing Partner of Cloudstone Venture Capital, an early-stage healthtech venture firm since October 2020. Cloudstone is also an investor of Eureka Therapeutics.
Ms. Willson has over 25 years of experience advising public and private companies on corporate finance, strategy, capital raising, valuation, mergers & acquisitions, and other matters. She has founded and run a midmarket investment banking boutique and worked with large Wall Street investment banks, including Kidder Peabody and Drexel Burnham.
Ms. Willson has served on private and non-profit boards and investment committees in various capacities. She teaches financial literacy. Ms. Willson holds a BA from Harvard and an MBA from Stanford Graduate School of Business.